Clinical trials: Antipsychotic
Schizophrenia, Major Depressive Disorder
PHARMO Institute Seroquel Safety Study
The purpose of this observational study is to study specific outcomes of interest in users of quetiapine compared with all other atypical antipsychotics and specifically olanzapine and risperidone.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Generalized Anxiety Disorder
- Trial name
- PHARMO II (NCT01342120)
- Volunteers
- 18,325 people
- Sponsor
- AstraZeneca
Neuroleptic-induced Tardive Dyskinesia
Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
TD is a troublesome and potentially irreversible side effect associated with the use of neuroleptics. While the newer neuroleptics are improved in this regard, they all still carry the risk of TD.
- Trial name
- NCT00310661
- Testing
- Sarizotan
- Where
- 2 sites in Canada, India
- Volunteers
- 60 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia
The purpose of this study is to determine whether aripiprazole injection into the shoulder or the buttocks produces similar effects in the body
- Trial name
- NCT01646827
- Testing
- Aripiprazole IM Depot
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Emergency Psychiatric, Cognition Disorder
DIAMOND-Lewy Guidelines for Antipsychotic Use in Older Patients
The goal of this observational study is to learn about current practices for the acute neuropsychiatric management of older adults during emergency department (ED) visits.
- Conditions
- Emergency Psychiatric, Cognition Disorder, Movement Disorders, Antipsychotics and Neuroleptics Toxicity
- Trial name
- NCT06357195
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Ohio State University
Schizophrenia
Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia
Main objective: To assess the efficacy of two antidepressants of different pharmacological families: citalopram (Selective serotonin reuptake inhibitors, SSRI) and reboxetine (Norepinephrine Reuptake inhibitor, NRI) as adjunct…
- Trial name
- NCT01300364
- Testing
- Reboxetine, citalopram (SSRI)
- Where
- Spain
- Volunteers
- 249 people
- Sponsor
- Fundació Sant Joan de Déu
Schizophrenia, Schizoaffective Disorder
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
Weight gain is a serious, common side effect of many antipsychotic medications. On average, the highest amounts of weight gain are found to occur in people taking clozaril and olanzapine, but with significant weight gain occuring…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Mood Disorders
- Trial name
- NCT00312598
- Testing
- Aripiprazole
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Drug-induced Weight Gain
Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine
This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.
- Trial name
- NCT05857566
- Testing
- RDX-002 + Olanzipine, Olanzapine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Response Pharmaceuticals
Schizophrenia
Pharmacogenomic and Pharmacoepigenomic Studies of Antipsychotic Drugs in First-Episode Schizophrenia
This study aims to explore the objective markers concerning schizophrenia risk and functional outcome from multiple dimensions such as multi-omics including genomics, proteomics, metabolomics, electrophysiology, imaging…
- Trial name
- NCT07102069
- Where
- China
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Tianjin Anding Hospital
Schizophrenia, Bipolar Affective Disorder
Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in…
- Trial name
- NCT07858565
- Testing
- Quetiapine (drug), quetiapine + aripiprazole, quetiapine + haloperidol
- Where
- Bosnia and Herzegovina
- Volunteers
- 500 people
- Sponsor
- Bosnalijek D.D
SSRI-Refractory Obsessive-Compulsive Disorder
Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
Objective: Although atypical antipsychotic drugs (AAPDs) have been found effective in the augmentation of serotonin reuptake inhibitors (SRIs) for treatment-resistant obsessive-compulsive disorder (OCD) in short terms trials…
- Trial name
- OCDDRUG (NCT00854919)
- Testing
- atypical antipsychotic drug, exposure response prevention
- Where
- Japan
- Sponsor
- Osaka City University
Schizophrenia
Safety and Efficacy of Zicronapine in Patients With Schizophrenia
To assess the effect of zicronapine versus risperidone on metabolic parameters comprising body weight, body mass index (BMI), waist circumference, levels of fasting blood lipids and glucose during 6 months of treatment.
- Trial name
- NCT01295372
- Testing
- Zicronapine, Risperidone
- Where
- 24 sites in Czechia, Estonia and 3 more
- Volunteers
- 160 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Efficacy of Selegiline in Negative Symptoms of Schizophrenia
Antipsychotic drugs are effective in treating the positive symptoms of schizophrenia; however their efficacy in treating negative symptoms is limited.
- Trial name
- NCT00456976
- Testing
- Selegiline
- Where
- Iran
- Volunteers
- 70 people
- Sponsor
- Tabriz University
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Delirium
Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium
Background: Delirium is an important problem in critical care. Its prevalence often reaches 75% in intensive care patients. Its occurrence is associated with numerous complications and deleterious consequences such as death…
- Trial name
- Haloquet (NCT01811459)
- Testing
- Quetiapine, Haloperidol
- Where
- Canada
- Volunteers
- 107 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders
Berberine as Adjuvant Treatment for Schizophrenia Patients
One double-blind, randomized, placebo-controlled trial is designed to examine whether berberine added to current antipsychotic drugs could produce significantly greater efficacy in reducing atypical antipsychotic-induced…
- Conditions
- Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Metabolic Syndrome x
- Trial name
- BER (NCT02983188)
- Testing
- Berberine, Antipsychotic Agents
- Where
- Hong Kong
- Volunteers
- 113 people
- Sponsor
- The University of Hong Kong
Delirium, Cognition Disorders
The MIND Study: Modifying the INcidence of Delirium
Delirium is associated with increased risk of death, prolonged stay, higher cost of care, and likely long-term brain deficits in survivors.
- Trial name
- NCT00096863
- Testing
- Ziprasidone, Haloperidol
- Where
- 5 sites in United States
- Volunteers
- 102 people
- Sponsor
- Vanderbilt University
Schizophrenia
iTBS for Increased Appetite Induced by Antipsychotics
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to…
- Trial name
- NCT05783063
- Testing
- Active iTBS
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Central South University
Schizophrenia
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone, paliperidone or aripiprazole) with prominent…
- Trial name
- NCT00616798
- Testing
- RO4917838, Standard antipsychotic therapy
- Where
- 73 sites in United States, Austria and 8 more
- Volunteers
- 323 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia Disorders
An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia
The study design is a de-escalation of current atypical AP treatment to X/T at a maintenance dose of X/T established either at 100 mg xanomeline/20 mg trospium chloride BID (total daily dose 200 mg xanomeline/40 mg trospium…
- Trial name
- NCT06924255
- Testing
- Xanomeline and Trospium Chloride
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Collaborative Neuroscience Research, LLC